ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

Lilly

Status

Conditions: Mesothelioma

Treatments: Drug: Cisplatin; Drug: Pemetrexed

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT00040625

H3E-US-JMFE

6093

Details and patient eligibility

About

This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have a proven diagnosis of malignant mesothelioma in patients not candidates for curative surgery
• Prior chemotherapy for your disease is allowed
• Measurable lesion is not required
• Have a adequate performance status
• Sign an informed consent form

Exclusion criteria

• You are excluded from this trial if you have received any investigational agent within 4 week before enrolling in this study
• You are excluded from this trial if you have received radiation within the previous 2 weeks
• You are excluded from this trial if you are a candidates for curative surgery